Praxis to Present on Study of Ulixacaltamide in Essential Tremor at MDS International Congress

  Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson's Disease and Movement Disorders®, taking place in Copenhagen, Denmark.

https://www.biospace.com/article/releases/praxis-precision-medicines-to-present-analyses-of-patient-focused-clinically-meaningful-endpoints-from-essential1-study-of-ulixacaltamide-in-essential-tremor-at-the-2023-mds-international-congress/